{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T18:49:33Z","timestamp":1781894973038,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Immun"],"DOI":"10.1038\/s41435-025-00322-w","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T11:09:39Z","timestamp":1741086579000},"page":"137-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Multi-omics clustering analysis carries out the molecular-specific subtypes of thyroid carcinoma: implicating for the precise treatment strategies"],"prefix":"10.1038","volume":"26","author":[{"given":"Zhenglin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7541-6743","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,4]]},"reference":[{"key":"322_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0866-1","volume":"17","author":"N Pstrag","year":"2018","unstructured":"Pstrag N, Ziemnicka K, Bluyssen H, Wesoly J. Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates. Mol Cancer. 2018;17:116.","journal-title":"Mol Cancer"},{"key":"322_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"322_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135:584\u201390.","journal-title":"Chin Med J"},{"key":"322_CR4","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.21037\/gs.2017.11.07","volume":"7","author":"SM Ferrari","year":"2018","unstructured":"Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Paparo SR, et al. Molecular testing in the diagnosis of differentiated thyroid carcinomas. Gland Surg. 2018;7:S19\u2013S29.","journal-title":"Gland Surg"},{"key":"322_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41574-020-00448-z","volume":"17","author":"M Schlumberger","year":"2021","unstructured":"Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2021;17:176\u201388.","journal-title":"Nat Rev Endocrinol"},{"key":"322_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/annurev-med-061512-105739","volume":"65","author":"T Carling","year":"2014","unstructured":"Carling T, Udelsman R. Thyroid cancer. Annu Rev Med. 2014;65:125\u201337.","journal-title":"Annu Rev Med"},{"key":"322_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.699805","volume":"12","author":"L Rossi","year":"2021","unstructured":"Rossi L, Materazzi G, Bakkar S, Miccoli P. Recent Trends in Surgical Approach to Thyroid Cancer. Front Endocrinol (Lausanne). 2021;12:699805.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"322_CR8","doi-asserted-by":"publisher","first-page":"5012","DOI":"10.1158\/1078-0432.CCR-16-0484","volume":"22","author":"F Raue","year":"2016","unstructured":"Raue F, Frank-Raue K. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy. Clin Cancer Res. 2016;22:5012\u201321.","journal-title":"Clin Cancer Res"},{"key":"322_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/thy.2018.0509","volume":"29","author":"T Ibrahimpasic","year":"2019","unstructured":"Ibrahimpasic T, Ghossein R, Shah JP, Ganly I. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects. Thyroid. 2019;29:311\u201321.","journal-title":"Thyroid"},{"key":"322_CR10","first-page":"3557","volume":"104","author":"R Giannini","year":"2019","unstructured":"Giannini R, Moretti S, Ugolini C, Macerola E, Menicali E, Nucci N, et al. Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like. J Clin Endocrinol Metab. 2019;104:3557\u201375.","journal-title":"J Clin Endocrinol Metab"},{"key":"322_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocr Pathol. 2022;33:27\u201363.","journal-title":"Endocr Pathol"},{"key":"322_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26343-3","volume":"12","author":"W Pu","year":"2021","unstructured":"Pu W, Shi X, Yu P, Zhang M, Liu Z, Tan L, et al. Single-cell transcriptomic analysis of the tumor ecosystems underlying initiation and progression of papillary thyroid carcinoma. Nat Commun. 2021;12:6058.","journal-title":"Nat Commun"},{"key":"322_CR13","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.semcancer.2020.11.013","volume":"79","author":"P Fallahi","year":"2022","unstructured":"Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, et al. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol. 2022;79:180\u201396.","journal-title":"Semin Cancer Biol"},{"key":"322_CR14","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","volume":"17","author":"MS Brose","year":"2016","unstructured":"Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:1272\u201382.","journal-title":"Lancet Oncol"},{"key":"322_CR15","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1002\/hed.25784","volume":"41","author":"C Suzuki","year":"2019","unstructured":"Suzuki C, Kiyota N, Imamura Y, Goto H, Suto H, Chayahara N, et al. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer. Head Neck. 2019;41:3023\u201332.","journal-title":"Head Neck"},{"key":"322_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12020-022-03113-9","volume":"78","author":"L Shi","year":"2022","unstructured":"Shi L, You Q, Wang J, Wang H, Li S, Tian R, et al. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC). Endocrine. 2022;78:68\u201376.","journal-title":"Endocrine"},{"key":"322_CR17","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2174\/0929867324666171006165942","volume":"26","author":"SM Ferrari","year":"2019","unstructured":"Ferrari SM, Centanni M, Virili C, Miccoli M, Ferrari P, Ruffilli I, et al. Sunitinib in the Treatment of Thyroid Cancer. Curr Med Chem. 2019;26:963\u201372.","journal-title":"Curr Med Chem"},{"key":"322_CR18","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1634\/theoncologist.2017-0096","volume":"22","author":"R Kollipara","year":"2017","unstructured":"Kollipara R, Schneider B, Radovich M, Babu S, Kiel PJ. Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer. Oncologist. 2017;22:1149\u201351.","journal-title":"Oncologist"},{"key":"322_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","volume":"6","author":"PC Iyer","year":"2018","unstructured":"Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018;6:68.","journal-title":"J Immunother Cancer"},{"key":"322_CR20","doi-asserted-by":"publisher","first-page":"6413","DOI":"10.1158\/1078-0432.CCR-21-0822","volume":"27","author":"C Even","year":"2021","unstructured":"Even C, Wang HM, Li SH, Ngan RK, Dechaphunkul A, Zhang L, et al. Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent\/Metastatic Nasopharyngeal Cancer. Clin Cancer Res. 2021;27:6413\u201323.","journal-title":"Clin Cancer Res"},{"key":"322_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112222","volume":"144","author":"X Hu","year":"2021","unstructured":"Hu X, Wang Z, Wang Q, Chen K, Han Q, Bai S, et al. Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering. Biomed Pharmacother. 2021;144:112222.","journal-title":"Biomed Pharmacother"},{"key":"322_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-020-02327-7","volume":"18","author":"Y Liu","year":"2020","unstructured":"Liu Y, Chen TY, Yang ZY, Fang W, Wu Q, Zhang C. Identification of hub genes in papillary thyroid carcinoma: robust rank aggregation and weighted gene co-expression network analysis. J Transl Med. 2020;18:170.","journal-title":"J Transl Med"},{"key":"322_CR23","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1038\/onc.2011.626","volume":"31","author":"G Tom\u00e1s","year":"2012","unstructured":"Tom\u00e1s G, Tarabichi M, Gacquer D, H\u00e9brant A, Dom G, Dumont JE, et al. A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic. Oncogene. 2012;31:4490\u20138.","journal-title":"Oncogene"},{"key":"322_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-16-S1-S7","volume":"16","author":"HJ Schulten","year":"2015","unstructured":"Schulten HJ, Al-Mansouri Z, Baghallab I, Bagatian N, Subhi O, Karim S, et al. Comparison of microarray expression profiles between follicular variant of papillary thyroid carcinomas and follicular adenomas of the thyroid. BMC Genomics. 2015;16:S7.","journal-title":"BMC Genomics"},{"key":"322_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9015713","volume":"2020","author":"Z Li","year":"2020","unstructured":"Li Z, Yang K, Zhang L, Wei C, Yang P, Xu W. Classification of Thyroid Nodules with Stacked Denoising Sparse Autoencoder. Int J Endocrinol. 2020;2020:9015713.","journal-title":"Int J Endocrinol"},{"key":"322_CR26","doi-asserted-by":"crossref","unstructured":"Lu X, Meng J, Zhou Y, Jiang L, Yan F. MOVICS: an R package for multi-omics integration and visualization in cancer subtyping. Bioinformatics. 2021:36:5539\u201341.","DOI":"10.1093\/bioinformatics\/btaa1018"},{"key":"322_CR27","doi-asserted-by":"publisher","first-page":"e0176278","DOI":"10.1371\/journal.pone.0176278","volume":"12","author":"P Chalise","year":"2017","unstructured":"Chalise P, Fridley BL. Integrative clustering of multi-level \u2018omic data based on non-negative matrix factorization algorithm. PloS one. 2017;12:e0176278.","journal-title":"PloS one"},{"key":"322_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/1467-9868.00293","volume":"63","author":"T Hastie","year":"2001","unstructured":"Hastie T, Tibshirani R, Walther G. Estimating the number of data clusters via the Gap statistic. J Roy Stat Soc B. 2001;63:411\u201323.","journal-title":"J Roy Stat Soc B"},{"key":"322_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48\u201361.","journal-title":"Cell"},{"key":"322_CR30","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.omto.2021.02.001","volume":"20","author":"J Meng","year":"2021","unstructured":"Meng J, Lu X, Zhou Y, Zhang M, Ge Q, Zhou J, et al. Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy. Mol Ther Oncolytics. 2021;20:410\u201321.","journal-title":"Mol Ther Oncolytics"},{"key":"322_CR31","unstructured":"Robertson AG, Kim J, Alahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171:540\u2013556.e25."},{"key":"322_CR32","doi-asserted-by":"publisher","first-page":"a019521","DOI":"10.1101\/cshperspect.a019521","volume":"8","author":"JE Audia","year":"2016","unstructured":"Audia JE, Campbell RM. Histone Modifications and Cancer. Cold Spring Harb Perspect Biol. 2016;8:a019521.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"322_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.655","volume":"11","author":"J Meng","year":"2021","unstructured":"Meng J, Lu X, Jin C, Zhou Y, Ge Q, Zhou J, et al. Integrated multi-omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer. Clin Transl Med. 2021;11:e655.","journal-title":"Clin Transl Med"},{"key":"322_CR34","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676\u201390.","DOI":"10.1016\/j.cell.2014.09.050"},{"key":"322_CR35","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016;6:827\u201337.","journal-title":"Cancer Discov"},{"key":"322_CR36","doi-asserted-by":"publisher","first-page":"e1195","DOI":"10.1371\/journal.pone.0001195","volume":"2","author":"Y Hoshida","year":"2007","unstructured":"Hoshida Y, Brunet JP, Tamayo P, Golub TR, Mesirov JP. Subclass mapping: identifying common subtypes in independent disease data sets. PloS One. 2007;2:e1195.","journal-title":"PloS One"},{"key":"322_CR37","doi-asserted-by":"publisher","first-page":"e15543","DOI":"10.1371\/journal.pone.0015543","volume":"5","author":"Y Hoshida","year":"2010","unstructured":"Hoshida Y. Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PloS one. 2010;5:e15543.","journal-title":"PloS one"},{"key":"322_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1055-6","volume":"18","author":"M Peng","year":"2019","unstructured":"Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18:128.","journal-title":"Mol Cancer"},{"key":"322_CR39","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1002\/cam4.3828","volume":"10","author":"Q Hu","year":"2021","unstructured":"Hu Q, Nonaka K, Wakiyama H, Miyashita Y, Fujimoto Y, Jogo T, et al. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer. Cancer Med. 2021;10:3129\u201338.","journal-title":"Cancer Med"},{"key":"322_CR40","doi-asserted-by":"crossref","unstructured":"Takahashi H, Kawaguchi T, Yan L, Peng X, Qi Q, Morris LGT, et al. Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. Cancers. 2020;12:1221.","DOI":"10.3390\/cancers12051221"},{"key":"322_CR41","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1101\/gr.240663.118","volume":"29","author":"L Garcia-Alonso","year":"2019","unstructured":"Garcia-Alonso L, Holland CH, Ibrahim MM, Turei D, Saez-Rodriguez J. Benchmark and integration of resources for the estimation of human transcription factor activities. Genome Res. 2019;29:1363\u201375.","journal-title":"Genome Res"},{"key":"322_CR42","unstructured":"Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676\u201390."},{"key":"322_CR43","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43018-021-00292-8","volume":"3","author":"B Liu","year":"2022","unstructured":"Liu B, Hu X, Feng K, Gao R, Xue Z, Zhang S, et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nat Cancer. 2022;3:108\u201321.","journal-title":"Nat Cancer"},{"key":"322_CR44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.annonc.2022.11.002","volume":"34","author":"I Hernandez-Verdin","year":"2023","unstructured":"Hernandez-Verdin I, Kirasic E, Wienand K, Mokhtari K, Eimer S, Loiseau H, et al. Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol. 2023;34:186\u201399.","journal-title":"Ann Oncol"},{"key":"322_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00678-8","volume":"10","author":"Y He","year":"2024","unstructured":"He Y, Duan S, Wang W, Yang H, Pan S, Cheng W, et al. Integrative radiomics clustering analysis to decipher breast cancer heterogeneity and prognostic indicators through multiparametric MRI. NPJ Breast Cancer. 2024;10:72.","journal-title":"NPJ Breast Cancer"},{"key":"322_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01805-8","volume":"29","author":"Y Ma","year":"2024","unstructured":"Ma Y, Li J, Zhao X, Ji C, Hu W, Ma Y, et al. Multi-omics cluster defines the subtypes of CRC with distinct prognosis and tumor microenvironment. Eur J Med Res. 2024;29:207.","journal-title":"Eur J Med Res"},{"key":"322_CR47","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/eci.12577","volume":"46","author":"Z Wang","year":"2016","unstructured":"Wang Z, Chen JQ, Liu JL, Qin XG. Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis. Eur J Clin Invest. 2016;46:146\u201357.","journal-title":"Eur J Clin Invest"},{"key":"322_CR48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12957-024-03539-7","volume":"22","author":"R Cong","year":"2024","unstructured":"Cong R, Ouyang H, Zhou D, Li X, Xia F. BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population. World J Surg Oncol. 2024;22:259.","journal-title":"World J Surg Oncol"},{"key":"322_CR49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1172\/JCI127515","volume":"130","author":"NS Sharma","year":"2020","unstructured":"Sharma NS, Gupta VK, Garrido VT, Hadad R, Durden BC, Kesh K, et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 2020;130:451\u201365.","journal-title":"J Clin Invest"},{"key":"322_CR50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.19.01882","volume":"38","author":"BA McGregor","year":"2020","unstructured":"McGregor BA, McKay RR, Braun DA, Werner L, Gray K, Flaifel A, et al. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and\/or Sarcomatoid Features. J Clin Oncol. 2020;38:63\u201370.","journal-title":"J Clin Oncol"},{"key":"322_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0419-z","volume":"13","author":"M Medici","year":"2015","unstructured":"Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Frates MC, et al. The variable phenotype and low-risk nature of RAS-positive thyroid nodules. BMC Med. 2015;13:184.","journal-title":"BMC Med"},{"key":"322_CR52","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.1158\/0008-5472.CAN-09-0024","volume":"69","author":"KA Miller","year":"2009","unstructured":"Miller KA, Yeager N, Baker K, Liao XH, Refetoff S, Di Cristofano A. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res. 2009;69:3689\u201394.","journal-title":"Cancer Res"},{"key":"322_CR53","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00432-019-03095-8","volume":"146","author":"L Zhang","year":"2020","unstructured":"Zhang L, Han L, He J, Lv J, Pan R, Lv T. A high serum-free fatty acid level is associated with cancer. J Cancer Res Clin Oncol. 2020;146:705\u201310.","journal-title":"J Cancer Res Clin Oncol"},{"key":"322_CR54","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/labinvest.2009.97","volume":"89","author":"CH Byon","year":"2009","unstructured":"Byon CH, Hardy RW, Ren C, Ponnazhagan S, Welch DR, McDonald JM, et al. Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4. Lab Invest. 2009;89:1221\u20138.","journal-title":"Lab Invest"}],"container-title":["Genes &amp; Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41435-025-00322-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-025-00322-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-025-00322-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T13:02:27Z","timestamp":1744894947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41435-025-00322-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,4]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1038\/s41435-025-00322-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.25.24303184","asserted-by":"object"}]},"ISSN":["1476-5470"],"issn-type":[{"value":"1476-5470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,4]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The current study was approved by Ethics Committee of The First Affiliated Hospital of Anhui Medical University (Quick-PJ2024-03-41). The samples included in our study were surgically removed tissues from patients, and our study was conducted as a retrospective analysis. Since this research did not influence clinical diagnosis or treatment, the ethics committee determined that participant consent could be waived under these circumstances.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}